This episode introduces the concept of computational nuclear oncology as a means to enhance the precision and personalization of radiopharmaceutical therapies (RPT) through paragnostic digital twins.
The speaker argues that static images are insufficient for clinical operation and proposes dynamic digital representations of patients that can be updated with real-time data, especially valuable in theranostics.
These digital twins, utilizing physiologically based pharmacokinetic (PBPK) models, aim to predict drug behavior and radiation dosimetry, moving beyond the limitations of current one-size-fits-all RPT approaches and potentially informing individualized treatment strategies and clinical trial designs.
The ethical, regulatory, and socioeconomic considerations of these emerging technologies are also acknowledged as important aspects of future implementation.
Comments